Applications Published 13 March 2002

Anti-inflammatory bioactive glass particulates
Usbiomaterials 1185247*

Supercritical fluid-assisted nebulisation and bubble drying
University Technology Corp 1185248*

Methods and compsns for treating solid tumours
Guilford Pharmaceuticals 1185249*

Enteric coated pharmaceutical formulation
Norton Healthcare 1185250*

A pharmaceutical compsn containing an active agent that is maintained in a solid amorphous form and method of making the same
Purepac Pharmaceutical 1185251*

Novel formulations comprising lipid-regulating agents
Abbott Laboratories 1185252*

Oral administration form for administering a fixed tramadol and diclofenac combination
Gruenenthal 1185253*

Orally administered pharmaceutical formulations of benzimidazole derivatives and the method of preparing the same
Carlsbad Technology 1185254*

Neuroprotective and retinoprotective ophthalmologic medicines
Rekik, Elyes Ben Mohamed Raouf; Rekik, Raouf 1185255*

Utilisation of a highly fluorinated oligomeric alkan in ophthalmology
Pharm Pur 1185256*

Treatment of acne using lipic acid
Perricone, Nicholas V 1185257*

Therapeutic uses for nitric oxide inhibitors
Cold Spring Harbour Laboratory 1185258*

Glycine cleavage system inhibitors as potential antpsychotics
Merck Patent 1185259*

Ascorbic acid compsn and method for treatment of aging or damaged skin
Bioderm 1185260*

IL-8 receptor antagonists
SmithKline Beecham 1185261*

Pharmaceutical compsns containing 8-chloro-3(b)-diethylaminoethyl)-4-methyl-7-ethoxycarbonyl-methxoy coumarin base and the salts thereof, with cholesterol-lowering activity
Fidia Farmaceutici 1185262*

Receptor agonists and antagonists
Respiratorius 1185263*

Process for the production of amorphous atorvastatin calcium
Ranbaxy Laboratories 1185264*

IL-8 receptor antagonists
SmithKline Beecham 1186265*

Amorphous form of fexofenadine hydrochloride
Ranbaxy Laboratories 1185266*

Dermal anaesthetic agents
Bridge Pharma 1185267*

The therapeutic use of D-threo-methylphenidate for the treatment of attention-deficit hyperactivity disorders
Medeva Europe 1185268*

Glycosyltransferase inhibitors
Abaron Biosciences 1185269*

IL-8 receptor antagonists
SmithKline Beecham 1185270*

IL-8 receptor antagonists
SmithKline Beecham 1185271*

Novel use of 1[4-(5-cyanoindol-3yl)-butyl]-4-(2-carbamoylbenzofuran-5-yl)piperazine and its physiologically acceptable salts
Merck 1185272*

Antifungal oral compsn containing itraconazole and process for preparing same
Hanmi Pharmaceutical 1185273*

Drug combinations comprising (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulphonyl)amino]pyrimidin-5-yl](3R, 5S)-3,5-dihydroxyhept-6-enoic acid and an inhibitor, inducer or substrate of P450 isoenzyme 3A4
AstraZeneca 1185274*

Aminopyrimidines as sorbitol dehydrogenase inhibitors
Pfizer Products 1185275*

Isophosphoramide mustard analogues and use thereof
Southern Research Institute 1185276*

Methods for modulating FXR receptor activity
Allergan Sales 1185277*

Fibrin polymer structure
Bristol-Myers Squibb 1185278*

Agents for treating malignant diseases using E1A-deficient adenoviruses with YB-1 protein-dependent replication
Holm, Per Sonne 1185279*

Water extract of camomile, process for obtaining it and use as an antifungal agent
CV Technologies 1185280*

Combination of glucosamine with herbal extracts of tripterygium, ligustrum and erycibe
Oxford Natural Products 1185281*

Formulations containing cranberry fruit, DL-methionine and Chinese herbs
Oxford Natural Products 1185282*

Novel therapeutic use of viral inflammation modulatory protein in blocking xenograft rejection
King Faisal Specialist Hospital and Research Centre 1185283*

47 human secreted proteins
Human Genome Sciences 1185284*

Mu o-conopeptides and their use as local anaesthetics
The University of Utah Research Foundation; Cognetix 1185286*

Use of estrogen receptor agonists or antagonists for treating growth, bone disorders
Karo Bio 1185287*

Hemoactive compsns and methods for their manufacture and use
Fusion Medical Technologies 1185288*

Amino acids from fish and soy proteins for improvement of insulin sensitivity
Universite Laval 1185289*

Therapeutic agent comprising a botulinum neurotoxin
BioteCon Gesellschaft fuer Biotechnologische Entwicklung und Consulting 1185291*

Use of interleukin-11 to treat hemorrhagic shock
Genetics Institute 1185292*

IL6RIL6 chimera for the treatment of neurodegenerative diseases
Yeda Research and Development 1185293*

Therapeutic methods and compsns for the treatment of impaired interpersonal and behavioural disorders
Institut Pasteur; Centre National de la Recherche Scientifique 1185294*

Adenosine diphosphate and activators thereof and their medical uses
Rademacher Group 1185295*

Prevention and treatment of amyloidogenic disease
Neuralab 1185296*

Streptococcus pneumoniae proteins and vaccines
Medimmune 1185297*

Prevention and treatment of amyloidogenic disease
Neuralab 1185298*

Use of antibodies against CD20 of rthe treatment of the graft versus host disease
Consiglio Nazionale della Richerche 1185299*

Method of treating carcinoma using antibody therapy and ameliorating side effects associated with such therapy
CRC for Biopharmaceutical Research 1185300*

Emulsion vehicle for poorly soluble drugs
Sonus Pharmaceuticals 1185301*

Specifically targeted catalytic anagonists and uses thereof
Genencor International; The Governing Council of the University of Toronto 1185302*

Inhibition of gastric acid production and/or secretion
Tachas, George 1185303*

Conjugates comprising cytokines and nucleic acids for treating proliferating cells
BioInnovation 1185304*

Ligand-conjugated oligomeric compounds
Isis Pharmaceuticals 1185305*

Use of viral vectors and charged molecules for gene therapy
Neurovir Therapeutics 1185306*

Use of viral vectors and charged molecules for gene therapy
Neurovir Therapeutics 1185306*